What can the biopharma industry learn from its rapid response to the COVID-19 pandemic?
In this expert interview with BioPharm International, James Blackwell, president of The Windshire Group, LLC, explains key actions the biopharma can learn from its response to the COVID-19 pandemic that can be applied to improve process development for non-pandemic development programs.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.